Konica Minolta Completes Sale of Tempus AI Shares Received From Ambry Genetics Transaction

TOKYO, Jun 30 (Pulse News Wire) – Konica Minolta,inc. (4902.T) completed the sale of all shares received as part of the transaction involving Ambry Genetics Corporation in March 2025.

As previously disclosed on November 5, 2024, the company transferred all of Ambry Genetics' stock to Tempus AI, Inc. in exchange for total consideration of $600 million yen, comprising cash of $375 million yen and Tempus AI shares worth $225 million yen. The acquired Tempus AI shares were sold gradually beginning in the first quarter of fiscal 2026, culminating in their complete disposal during the first quarter of fiscal 2027.

The proceeds from the share sales amounting to $159 million yen will be utilized to enhance the company's financial structure through debt reduction and shareholder returns. Additionally, Konica Minolta expects to recognize ¥2.900 billion as income from discontinued operations in the same quarter due to this transaction. This strategic move underscores the company’s commitment to optimizing capital efficiency and strengthening its financial position.